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Objectives. Most of human papillomavirus (HPV) infections are “cleared” by the immune system; however, in cases of immune
system suppression, infections could lead to development of malignancies. The aim of this study was to find out the frequency of
HR-HPV infection in early period after renal transplantation in recipients receiving immunosuppressive therapy and to follow the
progression of the infection up to one year. Methods. 43 female renal transplant recipients and 79 healthy female individuals as a
control group were enrolled in this investigation. For the detection of HPV infection, patients’ samples (blood and vaginal swabs)
were collected two weeks after transplantation with following collection of six months and one year. Different polymerase chain
reactions for HR-HPV genomic sequences detection and ELISA kit for detection of anti-HPV IgG antibodies were used. Results.
In this study, we show that frequency rate of HR-HPV infection has increased in the first year after transplantation from early stage
of immunosuppressive therapy (from 24% to 36%). Also an increase of HR-HPV load was detected over time, showing the highest
median viral load at sixth month after transplantation. Conclusions. From the obtained data, it follows that it is very important to
carefully monitor patients receiving immunosuppression therapy on progression of HR-HPV.
1. Introduction
Human papillomavirus (HPV) infections remain one of the
major global burdens even despite the very active use of
vaccination. Prevalence rate of HPV in East Europe is about
21.4% which is much higher in comparison with the global
prevalence of 11.7% [1]. Such high prevalence rate could
be related to absence of HPV screening programs and low
vaccination uptake because of poor knowledge on HPV
infection in the population [2, 3].
Based on association with cervical cancer and precursor
lesions, HPV can be classified as high-risk (HR-HPV) and
low-risk (LR-HPV) oncogenic types [4, 5]. LR-HPV types,
such as HPV 6 and 11, can cause common genital warts or
benign hyperproliferative lesions with very limited tendency
to malignant progression, while infection with HR-HPV
types, highlighting HPV 16 and 18, are associated with the
occurrence of premalignant and malignant cervical lesions
[6].
Most of HPV infections are “cleared” by the immune
system and do not result in clinical diseases in healthy
individuals; however, in cases of immune system suppression,
infections could lead to development of malignancies [7].
Although immunosuppressive therapy has improved
long-term graft and patient survival after renal transplan-
tation, it increases the cumulative occurrence of (pre)ma-
lignancies, especially those associated with viral infections
[8–10]. Declined cell-mediated immunity caused by
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the use of immunosuppressive therapy could increase
risk for HPV related anogenital (pre)malignancies in
renal transplant recipients, especially in countries where
the prevalence of HPV is high. Previous studies have
shown dramatic increase of HR-HPV infection up to 27%
[11, 12].
The objective of this study was to find out the frequency of
HR-HPV infection in early period after renal transplantation
in Latvian recipients and to follow the progression of the
infection up to one year.
2. Methods
43 female renal recipients (median age of 48; IQR = 39-
58), who received kidney allograft during 2013-2015, and 79
healthy female individuals (median age of 48; IQR = 42-
57), who were visiting gynaecologist for preventive exam-
ination, as a control group were enrolled in this investi-
gation. For the early detection of HPV infection, patients’
samples (whole blood and vaginal swabs) were collected
two weeks after transplantation with following collection
of six months and one year after the transplantation to
receive data on later periods. Chronic glomerulonephritis
(7%), hypertensive nephropathy (21%), chronic interstitial
nephritis (26%), and polycystic kidney disease (26%)were the
most common reasons for the subsequent transplantation. All
patients had received induction immunosuppression therapy
with monoclonal or polyclonal antibodies and steroid bolus
course. Initially immunosuppressive therapy consisted of
glucocorticoids (Prednisolone tapered down to 5 mg per day
during study period), antiproliferative drugs (Cell-cept  2 g
per day, tapered down to 1g per day if leucopenia appeared),
and calcineurin inhibitors (once per day tacrolimus with
trough level of 7-10 ng/ml during first 3 months after surgery
and 5-8 ng/ml thereafter or microemulsified formulation of
cyclosporine with trough level of 150-250 ng/ml during first
3 months after surgery and thereafter 100-200 ng/ml for
patients transplanted in 2013).
Aliquots of 200 𝜇l blood plasma were collected from
EDTA peripheral blood samples for further serological tests.
Blood plasma samples and cervical swab samples were stored
at -70∘C.
DNA from cervical swab samples was extracted using
phenol-chloroform method.
Beta- (𝛽-) globin PCR with appropriate primers was used
to determine the quality of isolated DNA [13].
Polymerase chain reaction (PCR)with consensus primers
MY9/MY11 was used for initial detection of high range HPV
types (HR-HPV and LR-HPV types) [14], HPV High Risk
Screen Real-TM Quant commercial qPCR kit (Sacace, Italy),
for quantitative detection of 12 types of HR-HPV (16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, and 59), and HPV typing with
semiquantitative viral load determination was done with the
Anyplex II HPV28 kit (Seegene, South Korea) in recipients’
cervical swab DNA samples.
ELISA commercial kit (MyBioSource, USA) was used
to detect IgG class antibodies against HR-HPV L1-capsids’
protein in recipients’ plasma (presence of these antibodies is
associated with HR-HPV clearance) [15, 16].
All statistical calculations and graphs were performed
using GraphPad Prism software version 6.0 for Windows
(GraphPad Software, San Diego, CA, USA). To test whether
the collected data are normally distributed, the D’Agostino
andPearson,Anderson-Darling, and Shapiro-Wilk normality
tests were applied. Statistical differences in the prevalence
of HPV infection were assessed by using Fisher’s exact
test. Statistical differences in viral load comparison were
calculated byMann–WhitneyU test. Becausemost of the data
was distributed not normally, results are expressed as median
and interquartile range (IQR) as dispersion characteristic,
and p-value of less than 0.05 (p< 0.05) was considered as
statistically significant. Pearson and Spearman testswere used
for correlation analysis.
The study was approved by the Ethics Committee of Riga
Stradins University, and written consent was obtained from
all patients.
3. Results
3.1. Presence of HPV Sequences Detected by PCR with
MY9/11 Consensus Primers
3.1.1. Recipients. Initial PCR results with consensus primers
MY9/11 showed that almost all recipients (42/43; 98%) were
positive on HPV genomic sequences in cervical swab DNA
samples. In 28/43 (65%) recipients’ cervical swab samples,
viral DNA was detected two weeks after transplantation, in
25 samples viral DNA had been preserved, and in 8 (total
33 recipients; 77%) additional recipients' presence of HPV
genomic sequences in cervical swab DNA samples appeared
(total 33/43 recipients; 77%) six months after transplantation.
One year after transplantation, 24 recipients were still positive
on HPV genomic sequences in cervical swab DNA samples
(17/24 were positive after two weeks and 6 months after
transplantation and another 7 recipients were positive only
after a time period of 6 months).
3.1.2. Control Group. Frequency rate of HPV sequences in
control group’s cervical swab DNA samples was found to be
significantly lower (38% [30/79] vs 65% [28/43, two weeks],
77% [33/43, six months], and 72% [31/43, one year], p< 0.05).
3.2. Presence of HR-HPV Sequences Detected by
Two Commercial Real-Time PCR Kits
3.2.1. Recipients. All HPVpositive samples were tested on the
presence of HR-HPV types using the Anyplex II HPV28
kit (Seegene, South Korea) and viral load was detected using
HPVHighRisk Screen Real-TMQuant commercial qPCR kit
(Sacace, Italy).
Overall HR-HPV genomic sequences were found in 65%
(28/43) of recipients. In early period after transplantation
(two weeks), HR-HPV presence was detected in 24% (10/43)
of recipients. In the following time periods, six months
and one year, HR-HPV frequency increased till 26% and
36%, respectively (Figure 1). McNemar’s test showed no
significance in HR-HPV positivity frequency over time in
the kidney transplant group. However, comparison of each

























































Figure 1: Presence of HR-HPV genomic sequences in recipients’
group cervical swab DNA samples two weeks, six months, and one
year after transplantation in comparison with control group. ∗p
value in comparison with control group.







Figure 2: HR-HPV median log copies detected in recipients’ group
cervical swab DNA samples two weeks, six months, and one year
after transplantation in comparison with control group.
recipient’s time points with control group showed significant
higher HR-HPV frequency in patients over the whole study
period (one year after transplantation vs control group,
p=0.0001; OR= 1.778, 95% CI: 1.322-2.407)
The highest HR-HPV median load was detected on the
sixth month after transplantation in comparison to two-week
and one-year period (3.98 log copies/105 cells, IQR: 1.10-6.66
versus 1.15 log copies/105 cells, IQR: 0.95-2.57, and 2.70 log
copies/105 cells, IQR: 1.55-5.07 [Figure 2]).
Although significant differences in HR-HPV load were
not found between recipients in the different time points,
decrease of median viral load after one year coincides with
significant decrease of average tacrolimus level in the same
period in comparison to 2 weeks and 6 months after trans-
plantation (3.68±1.83 ng/mL against 6.80±1.31 and 6.88±1.35
ng/mL, resp.) (Figure 3).
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Figure 4: HR-HPV load (log copies/105cells) detected in each
recipient’s cervical swab DNA samples two weeks, six months, and
one year after transplantation.
Following HR-HPV typeswere detected among the recip-
ients: 16, 18, 31, 33, 35, 51, 56, 66, 68, and 73. The most
dominant detected type was HPV-18, in 14/42 recipients
(33%), in comparison with HPV-56 (8/42, 19%), HPV-16
(7/42, 17%), HPV-35 (7/42, 17%), HPV-51 (6/42, 14%), HPV-
68 (5/42, 12%), HPV-33 (3/42, 7%), HPV-73 (2/42, 5%), HPV-
66 (1/42, 2%), and HPV-31 (1/42%, 2%), however without
statistical significance.
Patients’ data was stratified in three age groups. Patients
corresponding to the age group of 20 – 40 years showed
higher HR-HPV loads in their samples six months after
transplantation in comparison to patients of age over 40 years
(Figure 4).
Statistical analysis showed correlation between age and
HR-HPV load in a period of six months and one year after
transplantation (Figure 5).
3.2.2. Control Group. Among control group, HR-HPV infec-
tion was determined in 7/79 (8%) of women, significantly
lower frequency than in recipients’ group (two weeks, 23%;
p=0.05, six months, 26%; p=0.01, and one year, 36%; p<0.01).
Even though median HR-HPV load in control group was
higher than in recipients’ group two weeks after transplan-
tation (2.01 log copies/105 cells, IQR: 0.88-4.43 vs 1.15 log




















































Figure 5: HR-HPV load (log copies/105cells) and age correlation two weeks (a), six months (b), and one year (c) after transplantation.
copies/105 cells, IQR: 0.95-2.57, resp. [Figure 2]), there was no
significance.
The following HR-HPV types were detected: 16, 31, 33, 45
and 59.
3.3. Presence of IgG Antibodies against HR-HPV. IgG anti-
bodies against HR-HPV were detected in 15/43 (35%) recip-
ients, where 10 recipients were positive during all three
checking periods, two recipients only were positive at two-
week period, another one was positive during the first two
periods and negative at one year after transplantation, and
one recipient was positive during the last two periods and one
recipientwas positive only one year after transplantation. Two
recipients among those who became negative on HR-HPV
IgG antibodies were receiving Rituximab, B lymphocytes’
suppressor.
Plasma samples received from control group showed
significantly higher frequency rate of antibodies against HR-
HPV (51/79, 65%, p<0.001).
Interestingly, the number of the recipients positive for
both, HR-HPV sequences and antibodies, was increasing
over the time after transplantation and the number of
recipients positive for antibodies only decreased (Figure 6).
3.4. Allograft Rejection Cases. During the study, 11 out of
43 (26%) recipients developed different types of allograft
rejections, the most frequent of which was acute humoral
rejection (5 out of 11 cases) (Table 1). HR-HPV infection was
detected in 8 out of 11 (72%) recipients with rejection. Viral
infection was more frequently found in recipients with acute
humoral allograft rejection 2 weeks after transplantation (in
4 out of 5 recipients) (Table 1). Clinically significant HR-
HPV load (>3 log copies/105 cells) was found relatively
more frequently (3 out 8; 38%) in recipients with rejection
in comparison to recipients with normal allograft function,
where clinically significant viral load was found in 6 out of 20
(30%) recipients, although without statistical significance.
3.5. Histological Results. Presence of cervical intraepithelial
neoplasia (CIN) in one recipient was detected on the second
week after transplantation. After six months, two more recip-
ients had developed CIN I, and after one year, one of the three
























































Figure 6: Comparison of HR-HPV genomic presence in cervical
swab DNA samples together with presence of anti- HR-HPV L1
IgG antibodies in recipients’ group of different testing time points
compared with control group (∗p value).
DNA samples obtained from cervical swabs of recipients with
CIN high HR-HPV loads were detected and in two of them
coinfection with several HPV types was found (on the second
week, 1st recipient: HPV-68+HPV-18; 0.9 log copies/105 cells;
on the sixth month, 1st recipient: HPV-73; 2.1 log copies/105
cells, 2nd recipient: HPV-51; 9.6 log copies/105 cells, and 3rd
recipient:HPV-16+HPV-56; 7.47 log copies/105 cells; after one
year, 1st recipient: HPV-68+HPV-73; 1.55 log copies/105 cells,
2nd recipient: HPV-51+HPV-35+HPV-18; 2.7 log copies/105
cells [cytology results: normal], and 3rd recipient: HPV-
16+HPV-56; 7.48 log copies/105 cells) (Figure 4). Antibodies
against HR-HPV among these three recipients during all
three testing points were detected only in the 1st recipient’s
plasma samples, and the other two recipients were antibody
negative (Figure 7).
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Table 1: Number of recipients with different types of allograft rejection.
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Figure 7: Progression of CIN development in three recipients over the time in comparison to HR-HPV load with qPCR result interpretation
provided by manufacturers’ protocol (Sacace, Italy).
Cytology results of other recipients had shown normal
epithelium or such pathologies like atrophy, colpitis, and
cervicitis.
Among control group individuals, no CIN cases were
detected; however, one individual with very high HPV-16
load had atypical squamous cells of unknown significance
(A2-ASCUS).
4. Discussion
HPV persistent infection is strongly associated with devel-
opment of cervical cancer [17]. Despite the development of
new vaccines and increased use of themworldwide, HR-HPV
infections remain one of the major global health burdens.
This could be related to several circumstances like low uptake
of vaccine in some countries and absence of HPV screening
programs, as well as the fact that vaccines do not provide
defense from all HPV types. In Latvia, HPV vaccination as a
routine immunization approach was included in the National
Health Care Program in 2010; however, uptake of the vaccine
is not sufficient [3, 18].
TheHPV clearance fromhost’s organism requires an ade-
quate immune response; therefore, immunocompromised
individuals could be in the risk group of HPV persistent
infection development [19]. Because of received immuno-
suppressive therapy, renal allograft recipients in particular
are at high risk of developing persistent infection and HPV
associated cancer [20]. Recently published cohort study from
Denmark shows fivefold increased risk of genital warts (GW)
development associated with HPV infection in female kidney
transplant recipients in comparison with a nontransplanted
cohort [21]. Also, they showed a tendency of lower risk of
GW development in recipients that are undergoing dialysis
procedure due to graft failure after transplantation in com-
parison to recipients with normal graft function [21]. These
results also coincide with the results of another cohort study
from Australia, where the same tendency was shown only in
the development of anogenital cancer in the recipients [22].
This could be explained by chronic inflammation caused by
the exposure of recipients to uremic toxins and contact with
the dialysis system [23]. It was shown that dialysis could have
a dramatic impact on the innate immune response, especially
on macrophage activity, which is important because the
innate immune response plays a crucial role inHPVclearance
from the hosts’ organism preventing its persistence [23, 24].
However, our study found no significant differences between
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recipients with transplant rejection and recipients with nor-
mal transplant function in HR-HPV infection presence (72%
vs 62%, resp.) and high viral load frequencies (38% vs 30%
with >3 log copies/105 cells, resp.).
Another recent study showed that papillomatous lesions
in the oral cavity occurred in 36.1% of kidney allograft
recipients within 2 years after transplantation, where 25%
of recipients were positive on HPV-16 DNA sequence. More
than half of the studied group were male recipients [25].
This shows that HPV infection creates risk for not only
cervical cancer development in female recipients, but also
HPVassociated oral cancerwhich could be developed in both
male and female recipients.
That means a broader study on different HPV associated
cancer type developments, including anal cancer develop-
ment, whose incidence has been rising in the last few years,
is needed [26]. Such research would require not only female
but also male recipients’ study groups, because men are not
vaccinated against HPV and could be in higher risk of oral
and/or anal cancer development.
Another crucial factor that has an effect on the HPV
infection is the median age, 48, IQR= 39-58, of enrolled
recipients.Thismeans that they were not vaccinated, because,
as was written above, HPV vaccination was included in
Latvian National Health Care Program in 2010 and should
be done before the age of 15. Preventive vaccination against
HPV could help decrease HPV related cancer development
in the future; however, vaccination in adulthood is not very
efficient, especially in the case of immunosuppressant, due
to the fact that, after the first infection, HPV may persist
or be integrated in the hosts’ genome and therefore escape
from humoral immune response. Therefore, recipients, who
missed vaccination or were not able to be vaccinated during
childhood, are in the highest risk group of developing HPV
associated cancers. New ways to manage HPV infection
should be found.
The results of this research show a significantly higher
frequency rate of HR-HPV infection in renal transplant
recipients even in the early period after transplantation
(two weeks, 24%; p=0.05, six months, 26%; p=0.01, and one
year, 36%; p<0.01) in comparison with control group (8%).
These results show the growing tendency of HR-HPV infec-
tion frequency over the time in female recipients receiving
immunosuppressive therapy which indicates they are in the
risk group for HPV persistent infection development and
possible development of cervical cancer.
The fact that the highest level of HR-HPV load was
detected in recipients’ DNA samples six months after trans-
plantation in comparison with control group (median 3.98
log copies/105 cells, IQR: 1.10-6.66 against 2.01 log copies/105
cells, IQR: 0.88-4.43) is another evidence showing immuno-
suppression as a high-risk factor of development of HPV
persistent infection. The increase of HR-HPV viral load
detected in recipients’ samples from two weeks to six months
(from 1.15 log copies/105 cells, IQR: 0.95-2.57, to 3.98 log
copies/105 cells, IQR: 1.10-6.66, p<0.11) could be related to
the deepening of immune system suppression because the
mean CD4/CD8 ratio dropped from 1.95±1.07 till 1.51±0.87.
However, it is not clear why median viral load has started to
decrease in the one-year period after transplantation (till 2.70
log copies/105 cells, IQR: 1.55-5.07). It may be related to the
lowering of immunosuppressive drug dosages as significant
decrease of tacrolimus in recipients’ peripheral blood one
year after transplantation in comparison to 2 weeks and
6 months after transplantation (3.68±1.83 ng/mL against
6.80±1.31 and 6.88±1.35 ng/mL, resp.) (Figure 3) was found
in this study.
Significant correlation between the age of recipients
and HR-HPV load was found only in the period of six
months and one year after transplantation (Figure 5). This
again indicates that immunosuppressive therapy has major
impact onHR-HPV infection progression, as in these periods
after transplantation, recipients’ immunosuppression reaches
maximum effect. Also, recipients in the age ranges between
20 and 40 years were found to have higher viral loads.
This together with the correlation results indicates that this
group could be in higher risk of HR-HPVpersistent infection
development which plays an important role in cervical cancer
development (Figures 4 and 5).
Higher frequency rate of IgG antibodies against HR-
HPV L1 capsid protein in control group rather than in
recipients’ group (65% vs 35%, p=0.001) is another evidence
that immunosuppression plays an important role in the
development of persistent HR-HPV infection. Also, in some
recipients who had received Rituximab, which inhibits B
lymphocytes’ activity, no detectable antibodies against HR-
HPV in the early period after transplantation were found.
This could indicate the crucial role of immunosuppressive
therapy, including Rituximab, in suppression of humoral
immune response against HPV infection.
Interestingly, 14% of recipients who were previously
negative for the presence of HR-HPV genomic sequences
but positive for the presence of antibodies against HR-HPV
L1 protein became positive for viral sequences in the next
observation period after transplantation (Figure 6). This
could indicate HR-HPV reactivation and support hypothesis
that HPV could have a latent phase. It is still not clear
how HPV creates latency, research using mouse models have
shown that as long as the virus remains in the basal layer’s
stem cells, viral replication does not occur, but HPV can
become active in differentiated cells [27]. In the case of
HPV latent infection, presence of virus-specific antibodies
could not be considered as a marker of HPV clearance [28].
To evaluate development of HPV infection, more specific
markers which could indicate HPV latency need to be found.
Presence of cervical intraepithelial neoplasia is detected
only in recipients’ group and in all three cases HR-HPV
infection was found. Also, high viral loads were detected in
those patients (9.6, 7.48, and 2.1 log copies/105 cells). In these
cases, two facts should be pointed out: (1) in one recipient
with high HPV load (9.6 log copies/105 cells) six months after
transplantation clearance of CIN I followed with viral load
decrease to 2.7 log copies/105 cells was found after the one-
year period; (2) another recipient showed presence of CIN I
during all three testing points with low viral load (0.9, 2.1, and
1.55 log copies/105 cells) and was also positive for antibodies
against HR-HPV. The first fact shows that HR-HPV load
could potentially be a useful marker in the progression of
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HPV associated CIN development. The second fact points
out the presence of antibodies as a positive marker which
indicates HPV load decrease.
In this study, we show that frequency rate of HR-HPV
infection has increased in the first year after transplantation
from early stage of immunosuppressive therapy (from 24% to
36%). Together with increase in viral load (highest median
is detected on sixth month after transplantation, 3.98 log
copies/105 cells, IQR: 1.10-6.66), these results indicate that
female renal transplant recipients are at high risk of devel-
oping HPV associated cervical intraepithelial neoplasia of
different grade and possibly even cervical cancer. Therefore,
all female recipients need to be more carefully monitored
(twice a year during the first two years after surgery) for HPV
infection and development of CIN from the beginning of
immunosuppressive treatment application. The presence of
several cases of CIN I in recipients’ group but not in control
group could support this statement. Early detection of HR-
HPV infection in female renal transplant recipients could
help prevent development of cervical cancer in the future.
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